• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Aquinox Pharmaceuticals

edit

Aquinox Pharmaceuticals Inc., a pharmaceutical company, engages in discovery, development, and commercialization of small molecule therapeutics for the treatment of cancer and inflammatory disease. It offers AQX-MN100, a drug used to treat cancer and inflammatory disease, as well as SH2-containing inositol 5’-phosphatase inhibition program for blood cell recovery. The company was founded in 2004 and is based in Vancouver, Canada.

Recent Milestones

edit

• 
  Aquinox Pharmaceuticals received $18M in Series C funding. (4/3/13)
  Posted 4/8/13 at 11:55pm via yahoo.com
• 
  Aquinox Pharmaceuticals received $25M in Series B funding. (6/17/10)
  Posted 6/17/10 at 7:42pm via aqxpharma.com
• 
  Aquinox Pharmaceuticals added David J. Main as President & CEO.
  Posted 6/17/10 at 7:42pm
• 
  Aquinox Pharmaceuticals added Thomas MacRury as EVP & Chief Operating Officer.
  Posted 6/17/10 at 7:42pm
• 
  Aquinox Pharmaceuticals added Stephen Majlath as Director, Finance.
  Posted 6/17/10 at 7:42pm

Videos

Screenshots

edit

Sources

1. Aquinox Pharmaceuticals completes US $25 million Series B financing (aqxpharma.com) [edit]
2. Aquinox Pharmaceuticals Completes US $18 million Series C Financing (finance.yahoo.com) [edit]